{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:27:59Z","timestamp":1789835279902,"version":"4.0.1"},"reference-count":51,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Rho-associated kinase (ROCK) inhibitors have gained popularity as novel treatment options in the management of glaucoma and corneal endothelial disorders. Among the various ocular side effects, reticular corneal epithelial edema has been most frequently reported, mainly after treatment with netarsudil. To explain the potential mechanisms, we comparatively analyzed the effects of ripasudil and netarsudil on corneal endothelial and epithelial function in vitro. Primary human corneal endothelial and epithelial cells were incubated with netarsudil dihydrochloride and ripasudil hydrochloride dihydrate for up to 7 days. Gene and protein expression analyses were performed by real-time PCR and immunocytochemistry. Functional assays assessed the cell migration, proliferation, viability, Na+\/K+-ATPase activity, transcellular electrical resistance, and FITC\u2013dextran permeability. Reticular bullous corneal epithelial edema was observed in a patient following netarsudil 0.02%\/latanoprost 0.005% ophthalmic solution (Roclanda\u00ae) for elevated intraocular pressure. In the subsequent laboratory analyses, both netarsudil and ripasudil were found to improve the corneal endothelial pump and barrier function, but they showed differential effects on corneal epithelial cells. Whereas ripasudil improved the epithelial barrier function by upregulating major components of the tight and adherens junctions and reducing paracellular permeability, netarsudil had no or even adverse effects on the epithelial barrier properties by downregulating the expression levels of cell-junction-associated genes. The expression changes normalized after discontinuation of ROCK inhibitors. The findings support the concept that ROCK inhibitors can act as a double-edged sword by having beneficial effects on corneal endothelial cells and adverse effects on epithelial cells.<\/jats:p>","DOI":"10.3390\/cells14040258","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T09:36:05Z","timestamp":1739266565000},"page":"258","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Drug- and Cell-Type-Specific Effects of ROCK Inhibitors as a Potential Cause of Reticular Corneal Epithelial Edema"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8423-7395","authenticated-orcid":false,"given":"Ursula","family":"Schl\u00f6tzer-Schrehardt","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9768-2049","authenticated-orcid":false,"given":"Andreas","family":"Gie\u00dfl","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0141-120X","authenticated-orcid":false,"given":"Matthias","family":"Zenkel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3250-3855","authenticated-orcid":false,"given":"Alexander","family":"Bartsch","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2275-5263","authenticated-orcid":false,"given":"Naoki","family":"Okumura","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe 610-0321, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Koizumi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe 610-0321, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto 602-0841, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3465-9837","authenticated-orcid":false,"given":"Theofilos","family":"Tourtas","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich E.","family":"Kruse","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","article-title":"Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension","volume":"125","author":"Tanna","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","article-title":"Ripasudil: First global approval","volume":"74","year":"2014","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-018-0877-7","article-title":"Netarsudil Ophthalmic Solution 0.02%: First Global Approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s12325-020-01277-2","article-title":"Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy\/Safety Analysis of Phase 3 MERCURY-1 and -2","volume":"37","author":"Asrani","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/aos.12829","article-title":"One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension","volume":"94","author":"Tanihara","year":"2016","journal-title":"Acta Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients with Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00417-021-05379-7","article-title":"Intraocular pressure-lowering efficacy and ocular safety of Rho-kinase inhibitor in glaucoma: A meta-analysis and systematic review of prospective randomized trials","volume":"260","author":"Wu","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1007\/s12325-023-02550-w","article-title":"Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET)","volume":"40","author":"Araie","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1038\/s41433-024-03342-4","article-title":"Ocular effects of Rho kinase (ROCK) inhibition: A systematic review","volume":"38","author":"Lin","year":"2024","journal-title":"Eye"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102069","DOI":"10.1016\/j.ajoc.2024.102069","article-title":"Crystalline keratopathy following long-term netarsudil therapy","volume":"35","author":"Cummings","year":"2024","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100800","DOI":"10.1016\/j.ajoc.2020.100800","article-title":"Netarsudil-associated epithelial keratopathy","volume":"19","author":"Ramakrishnan","year":"2020","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/IJG.0000000000001636","article-title":"Reticular Epithelial Edema: An Uncommon Side Effect of ROCK\/NET Inhibitor Netarsudil","volume":"29","author":"Chen","year":"2020","journal-title":"J. Glaucoma"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2020.04.002","article-title":"Reticular Bullous Epithelial Edema in Corneas Treated with Netarsudil: A Case Series","volume":"217","author":"Wisely","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/ICO.0000000000002621","article-title":"Transient Reticular Cystic Corneal Epithelial Edema with Topical Netarsudil: A Case Series and Review","volume":"40","author":"LoBue","year":"2021","journal-title":"Cornea"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101638","DOI":"10.1016\/j.ajoc.2022.101638","article-title":"Two pediatric cases of reticular corneal epithelial edema associated with netarsudil","volume":"27","author":"Liebman","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/ICO.0000000000002694","article-title":"Honeycomb Epithelial Edema Associated with Rho Kinase Inhibition: A Case Series and Review of the Literature","volume":"41","author":"Lyons","year":"2022","journal-title":"Cornea"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101287","DOI":"10.1016\/j.ajoc.2022.101287","article-title":"Netarsudil-associated reticular corneal epithelial edema","volume":"25","author":"Tran","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/ICO.0000000000000240","article-title":"New therapeutic modality for corneal endothelial disease using Rho-associated kinase inhibitor eye drops","volume":"33","author":"Koizumi","year":"2014","journal-title":"Cornea"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/ICU.0000000000000748","article-title":"Rho kinase (ROCK) inhibitors in the management of corneal endothelial disease","volume":"32","author":"Syed","year":"2021","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/DDDT.S435522","article-title":"The Role of Rho Kinase Inhibitors in Corneal Diseases","volume":"18","author":"Futterknecht","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_21","first-page":"2646904","article-title":"Application of Rho Kinase Inhibitors for the Treatment of Corneal Endothelial Diseases","volume":"2017","author":"Okumura","year":"2017","journal-title":"J. Ophthalmol."},{"key":"ref_22","first-page":"1185","article-title":"Cultured Cells and ROCK Inhibitor for Bullous Keratopathy","volume":"379","author":"Kinoshita","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/ICO.0000000000002642","article-title":"A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy","volume":"40","author":"Kinoshita","year":"2021","journal-title":"Cornea"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/ICO.0000000000002691","article-title":"Pilot Study of Corneal Clearance with the Use of a Rho-Kinase Inhibitor After Descemetorhexis Without Endothelial Keratoplasty for Fuchs Endothelial Corneal Dystrophy","volume":"40","author":"Davies","year":"2021","journal-title":"Cornea"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/ICO.0000000000002437","article-title":"Descemet Stripping Only Supplemented with Topical Ripasudil for Fuchs Endothelial Dystrophy 12-Month Outcomes of the Sydney Eye Hospital Study","volume":"40","author":"Moloney","year":"2021","journal-title":"Cornea"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/ICO.0000000000001883","article-title":"Use of Topical Rho Kinase Inhibitors in the Treatment of Fuchs Dystrophy After Descemet Stripping Only","volume":"38","author":"Macsai","year":"2019","journal-title":"Cornea"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/IJG.0000000000001516","article-title":"Reticular Corneal Edema or Corneal Honeycombing in Eyes Treated with Netarsudil: A Case Series","volume":"29","author":"Moumneh","year":"2020","journal-title":"J. Glaucoma"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.4103\/ijo.IJO_2865_21","article-title":"Reticular epithelial corneal edema as a novel side-effect of Rho Kinase Inhibitors: An Indian scenario","volume":"70","author":"Bhargava","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4103\/ojo.ojo_2_22","article-title":"Reticular corneal epithelial edema with topical netarsudil","volume":"16","author":"Parmar","year":"2023","journal-title":"Oman J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Polisetti, N., Sorokin, L., Okumura, N., Koizumi, N., Kinoshita, S., Kruse, F.E., and Schl\u00f6tzer-Schrehardt, U. (2017). Laminin-511 and -521-based matrices for efficient ex vivo-expansion of human limbal epithelial progenitor cells. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-04916-x"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8488","DOI":"10.1167\/iovs.11-8361","article-title":"Regulation of lysyl oxidase-like 1 (LOXL1) and elastin-related genes by pathogenic factors associated with pseudoexfoliation syndrome","volume":"52","author":"Zenkel","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Keller, K.E., and Kopczynski, C. (2020). Effects of Netarsudil on Actin-Driven Cellular Functions in Normal and Glaucomatous Trabecular Meshwork Cells: A Live Imaging Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113524"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Peh, G.S.L., Bandeira, F., Neo, D., Adnan, K., Hartono, Y., Ong, H.S., Naso, S., Venkatraman, A., Gomes, J.A.P., and Kocaba, V. (2023). Effects of Rho-Associated Kinase (Rock) Inhibitors (Alternative to Y-27632) on Primary Human Corneal Endothelial Cells. Cells, 12.","DOI":"10.3390\/cells12091307"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ajo.2020.12.006","article-title":"Potential Functional Restoration of Corneal Endothelial Cells in Fuchs Endothelial Corneal Dystrophy by ROCK Inhibitor (Ripasudil)","volume":"224","author":"Zenkel","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"He, Z., Forest, F., Gain, P., Rageade, D., Bernard, A., Acquart, S., Peoc\u2019h, M., Defoe, D.M., and Thuret, G. (2016). 3D map of the human corneal endothelial cell. Sci. Rep., 6.","DOI":"10.1038\/srep29047"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.bbamem.2007.07.012","article-title":"Adherens and tight junctions: Structure, function and connections to the actin cytoskeleton","volume":"1778","author":"Hartsock","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Pagano, L., Lee, J.W., Posarelli, M., Giannaccare, G., Kaye, S., and Borgia, A. (2023). ROCK Inhibitors in Corneal Diseases and Glaucoma-A Comprehensive Review of These Emerging Drugs. J. Clin. Med., 12.","DOI":"10.3390\/jcm12216736"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ajo.2021.03.006","article-title":"Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy","volume":"227","author":"Price","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/jop.2022.0069","article-title":"Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy","volume":"38","author":"Lindstrom","year":"2022","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1167\/tvst.10.4.18","article-title":"The ROCK Inhibitor Ripasudil Shows an Endothelial Protective Effect in Patients with Low Corneal Endothelial Cell Density After Cataract Surgery","volume":"10","author":"Fujimoto","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/ICO.0000000000003578","article-title":"Prospective Assessment of Adjuvant Netarsudil Use in Patients Undergoing Descemet Stripping Only","volume":"44","author":"Bal","year":"2024","journal-title":"Cornea"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Garcia, M.A., Nelson, W.J., and Chavez, N. (2018). Cell-Cell Junctions Organize Structural and Signaling Networks. Cold Spring Harb. Perspect. Biol., 10.","DOI":"10.1101\/cshperspect.a029181"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1152\/physiol.00034.2009","article-title":"Rho signaling and tight junction functions","volume":"25","author":"Terry","year":"2010","journal-title":"Physiology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"103609","DOI":"10.1016\/j.drudis.2023.103609","article-title":"Targeting Rho kinase to restore endothelial barrier function following vascular scaffold implantation","volume":"28","author":"Tesfamariam","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"10423","DOI":"10.1074\/jbc.M007136200","article-title":"Regulation of tight junction permeability and occludin phosphorylation by Rhoa-p160ROCK-dependent and -independent mechanisms","volume":"276","author":"Hirase","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12987-022-00336-w","article-title":"Effects of fasudil on blood-brain barrier integrity","volume":"19","author":"Sato","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1167\/iovs.09-4421","article-title":"Formation and disassembly of adherens and tight junctions in the corneal endothelium: Regulation by actomyosin contraction","volume":"51","author":"Ramachandran","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cm.20472","article-title":"Rho-kinase\/ROCK: A key regulator of the cytoskeleton and cell polarity","volume":"67","author":"Amano","year":"2010","journal-title":"Cytoskeleton"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/jop.2017.0023","article-title":"Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma","volume":"34","author":"Lin","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1600-0420.2005.00551.x","article-title":"Monoamine receptors in human corneal epithelium and endothelium","volume":"84","author":"Grueb","year":"2006","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1167\/iovs.18-23944","article-title":"New Human Organotypic Corneal Tissue Model for Ophthalmic Drug Delivery Studies","volume":"59","author":"Kaluzhny","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/4\/258\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:31:25Z","timestamp":1760027485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/4\/258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cells14040258"],"URL":"https:\/\/doi.org\/10.3390\/cells14040258","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}